Skip to the page

Data / Drug companies / Chengdu Shengnuo Biopharm Co. Ltd.

Chengdu Shengnuo Biopharm Co. Ltd.: 19 products in the FDA NDC directory, labeler code 32861

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Chengdu Shengnuo Biopharm Co. Ltd. (labeler code 32861) lists 19 products in the FDA National Drug Code Directory. By type: 19 bulk ingredients. Its main marketing category is bulk ingredients. The newest product started marketing on April 1, 2026.

The request: Watch Chengdu Shengnuo Biopharm Co. Ltd. (FDA labeler code 32861): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
32861
Products in commercial distribution
19
Packages
29
Finished drugs by generic name
0
Prescription products
0
Over the counter products
0
Started marketing in the last 12 months
4
Earliest marketing start
December 7, 2011
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Bulk ingredients1473.7%
Bulk ingredients for compounding526.3%

Products by type

TypeProductsShare
Bulk ingredients19100%

Dosage forms

Dosage formProductsShare
Powder19100%

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Tirzepatide32861-0013PowderBulk ingredientsApril 1, 2026
Abaloparatide32861-0015PowderBulk ingredientsMarch 1, 2026
Semaglutide32861-0014PowderBulk ingredients for compoundingFebruary 1, 2026
Tirzepatide32861-0013PowderBulk ingredients for compoundingNovember 10, 2025
Terlipressin acetate32861-0012PowderBulk ingredientsJuly 1, 2025
Semaglutide32861-0011PowderBulk ingredients for compoundingDecember 1, 2024
Semaglutide32861-0011PowderBulk ingredients for compoundingDecember 1, 2024
Semaglutide32861-0011PowderBulk ingredients for compoundingApril 25, 2024
Semaglutide32861-0011PowderBulk ingredientsJanuary 18, 2023
Linaclotide32861-0010PowderBulk ingredientsApril 8, 2021
Ganirelix acetate32861-0009PowderBulk ingredientsFebruary 4, 2019
Teriparatide32861-0008PowderBulk ingredientsAugust 23, 2018
Ziconotide acetate32861-0007PowderBulk ingredientsAugust 23, 2018
Lanreotide acetate32861-0006PowderBulk ingredientsDecember 13, 2017
Octreotide acetate32861-0005PowderBulk ingredientsAugust 18, 2015
Icatibant acetate32861-0004PowderBulk ingredientsAugust 21, 2014
Liraglutide32861-0003PowderBulk ingredientsJanuary 20, 2014
Eptifibatide32861-0002PowderBulk ingredientsJune 13, 2013
Bivalirudin32861-0001PowderBulk ingredientsDecember 7, 2011

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.